Updated version of this database is available at ThpDB2

Detailed description page of THPdb

This page displays user query in tabular form.

Th1237 details
Primary information
ID1849
ThPP IDTh1237
Therapeutic Peptide/Protein NameSomatropin recombinant
SequenceFPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQT view full sequnce in fasta
Functional ClassificationIb
Molecular Weight22129
Chemical FormulaC990H1532N262O300S7
Isoelectric Point5.27
Hydrophobicity-0.411
Melting Point (℃)76 °C at
Half LifeNA
DescriptionRecombinant human growth hormone (somatotropin) 191 residues, MW 22.1 kD, synthesized in E. coli
Indication/DiseaseFor treatment of dwarfism, acromegaly and prevention of HIV-induced weight loss
PharmacodynamicsUsed in the treatment of dwarfism and growth failure, growth hormone (hGH) stimulates skeletal growth in pediatric patients with growth failure due to a lack of adequate secretion of endogenous GH. Skeletal growth is accomplished at the epiphyseal plates at the ends of a growing bone. Growth and metabolism of epiphyseal plate cells are directly stimulated by GH and one of its mediators, IGF-I (insulin-like growth factor).
Mechanism of ActionhGH binds to the human growth hormone receptor (GHR). Upon binding, hGH causes dimerization of GHR, activation of the GHR-associated JAK2 tyrosine kinase, and tyrosyl phosphorylation of both JAK2 and GHR. These events recruit and/or activate a variety of signaling molecules, including MAP kinases, insulin receptor substrates, phosphatidylinositol 3' phosphate kinase, diacylglycerol, protein kinase C, intracellular calcium, and Stat transcription factors. These signaling molecules contribute to the GH-induced changes in enzymatic activity, transport function, and gene expression that ultimately culminate in changes in growth and metabolism.
ToxicityNA
MetabolismNA
AbsorptionNA
Volume of DistributionNA
Clearance2.3 +/- 1.8 mL/min/kg [GHD patients (IV 33 ng/kg/min)]
CategoriesHormones, Hormone Substitutes, and Hormone Antagonists
Patents NumberCA1326439,CA2252535
Date of IssueMostly fro
Date of ExpiryMostly 202
Drug InteractionThe therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Bazedoxifene, Chlorotrianisene, Conjugated Equine Estrogens, Cortisone acetate, Dienestrol, Diethylstilbestrol, Estradiol, Estriol, Estrone, Ethinyl Estradiol.
TargetGrowth hormone receptor, Prolactin receptor
Information of corresponding available drug in the market
Brand NameBioTropin
CompanyBiotech General
Brand DiscriptionBitropin is a recombinant human growth hormone
Prescribed forIt is indicate dfor short stature due to pitutary growth hormone deficency, turner Syndorme, Children suffering from renal insuuficiency.
Chemical NameNA
FormulationNA
Physcial AppearancePowder and Solvent for Solution
Route of AdministrationSubcutaneous
Recommended DosageThe reequired dose is 10mg/ml
Contraindicationchildren with closed epiphyses.
Side Effectsmay lead to loss or increase of adipose tissue as well as punctual haemorrhage and bruising at the injection site.
Useful Linkhttps://www.old.health.gov.il/units/pharmacy/trufot/alonim/Bio_Tropin_10mg_dr_1316590559720.pdf , https://www.drugbank.ca/drugs/DB00052
PubMed ID2688, 2903866, 16702112, 5675428
3-D StructureN.A.
Primary information
ID1850
ThPP IDTh1237
Therapeutic Peptide/Protein NameSomatropin recombinant
SequenceFPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQT view full sequnce in fasta
Functional ClassificationIb
Molecular Weight22129
Chemical FormulaC990H1532N262O300S7
Isoelectric Point5.27
Hydrophobicity-0.411
Melting Point (℃)76 °C at
Half LifeNA
DescriptionRecombinant human growth hormone (somatotropin) 191 residues, MW 22.1 kD, synthesized in E. coli
Indication/DiseaseFor treatment of dwarfism, acromegaly and prevention of HIV-induced weight loss
PharmacodynamicsUsed in the treatment of dwarfism and growth failure, growth hormone (hGH) stimulates skeletal growth in pediatric patients with growth failure due to a lack of adequate secretion of endogenous GH. Skeletal growth is accomplished at the epiphyseal plates at the ends of a growing bone. Growth and metabolism of epiphyseal plate cells are directly stimulated by GH and one of its mediators, IGF-I (insulin-like growth factor).
Mechanism of ActionhGH binds to the human growth hormone receptor (GHR). Upon binding, hGH causes dimerization of GHR, activation of the GHR-associated JAK2 tyrosine kinase, and tyrosyl phosphorylation of both JAK2 and GHR. These events recruit and/or activate a variety of signaling molecules, including MAP kinases, insulin receptor substrates, phosphatidylinositol 3' phosphate kinase, diacylglycerol, protein kinase C, intracellular calcium, and Stat transcription factors. These signaling molecules contribute to the GH-induced changes in enzymatic activity, transport function, and gene expression that ultimately culminate in changes in growth and metabolism.
ToxicityNA
MetabolismNA
AbsorptionNA
Volume of DistributionNA
Clearance2.3 +/- 1.8 mL/min/kg [GHD patients (IV 33 ng/kg/min)]
CategoriesHormones, Hormone Substitutes, and Hormone Antagonists
Patents NumberCA1326439,CA2252535
Date of IssueMostly fro
Date of ExpiryMostly 202
Drug InteractionThe therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Bazedoxifene, Chlorotrianisene, Conjugated Equine Estrogens, Cortisone acetate, Dienestrol, Diethylstilbestrol, Estradiol, Estriol, Estrone, Ethinyl Estradiol.
TargetGrowth hormone receptor, Prolactin receptor
Information of corresponding available drug in the market
Brand NameNutropinAQ
CompanyGenentech Inc.
Brand DiscriptionNutropin AQ [somatropin (rDNA origin)] for Injection is a human growth hormone (hGH) produced by recombinant DNA technology. Nutropin AQ has 191 amino acid residues and a molecular weight of 22,125 daltons. The amino acid sequence of the product is identical to that of pituitary-derived hGH. Nutropin AQ may contain not more than fifteen percent deamidated GH at expiration. The deamidated form of GH has been extensively characterized and has been shown to be safe and fully active.
Prescribed forTreating certain children or adults when the body does not produce enough growth hormone. It is also used to treat certain children who are not growing normally due to Turner syndrome or other conditions (eg, chronic kidney problems, idiopathic short stature).
Chemical NameNA
FormulationEach pen cartridge or NuSpin contain either 5 mg, 10 mg or 20 mg of somatropin formulated in 17.4 mg sodium chloride, 5 mg phenol, 4 mg polysorbate 20, and 10 mM sodium citrate
Physcial AppearanceSterile liquid
Route of AdministrationSubcutaneous
Recommended DosageA weekly dosage of up to 0.3 mg/kg of body weight divided into daily subcutaneous injections is recommended for Idiopathic Short Stature (ISS)
ContraindicationAcute Critical Illness, Prader-Willi Syndrome (PWS) In Children, Active Malignancy, Diabetic Retinopathy, Hypersensitivity, Closed Epiphysis
Side EffectsAbnormal or decreased touch sensation, bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
Useful Linkhttps://www.drugs.com/cdi/nutropin-aq.html , https://www.medicines.org.uk/emc/medicine/14244 , http://www.rxlist.com/nutropin-aq-drug/side-effects-interactions.htm
PubMed ID2688, 2903866, 16702112, 5675429
3-D StructureN.A.